Title Center Name Physician

Using Virtual Reality (VR) Models for Preoperative Planning

NCT ID : 03334344
Protocol Number : VR Models

Urology and Urologic Oncology

Linehan

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I

Brain Tumors & Neuroscience

Kesari

A Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab

NCT ID : 03538314
Protocol Number : UV1-hTERT-MM-103
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day

Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II

Brain Tumors & Neuroscience

Kesari

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

NCT ID : 03480646
Protocol Number : 1205-201
Phase : Ib/II

Urology and Urologic Oncology

Twardowski

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

NCT ID : 02922764
Protocol Number : RGX-104-001
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day

The Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With LG NMIBC at Intermediate Risk of Recurrence

NCT ID : 03558503
Protocol Number : TC-BC-12
Phase : 2

Urology and Urologic Oncology

Linehan

A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)

NCT ID : 03131960
Phase : 3

Brain Tumors & Neuroscience

Achrol

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3

Melanoma, Skin and Soft Tissue Tumors

O'Day

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (INTACT)

NCT ID : 03393000
Phase : 3
Kesari

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT ID : 03515538
Phase : 2a

Brain Tumors & Neuroscience

Kesari

A Feasibility Study of the Nativis Voyager System in Patients With Newly-Diagnosed Glioblastoma Multiforme (GBM)

NCT ID : 03276268
Phase : Feasibility

Brain Tumors & Neuroscience

Barkhoudarian

A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03463265
Phase : 2

Brain Tumors & Neuroscience

Kesari

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT ID : 03633110
Phase : 1 and 2

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Urology and Urologic Oncology

Twardowski

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT ID : 03425643
Phase : IIB or IIIA

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Onugha

Phase I Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Pembrolizumab in Subjects with Advanced Melanoma

NCT ID : 02565992
Protocol Number : VLA-011 (20160939)
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day

Phase Ib Study of Intratumoral CAVATAK(TM) (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

NCT ID : 02307149
Protocol Number : VLA-013 (20150760)
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day

Phase 1B, Multicenter, Open-Label Study Of Marizomib Combined with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma

NCT ID : 02903069
Protocol Number : MRZ-112 (20161905)
Phase : Ib

Brain Tumors & Neuroscience

Kesari

A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR Study)

NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : III

Brain Tumors & Neuroscience

Kesari

A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas

NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II

Brain Tumors & Neuroscience

Kesari

A Feasibility Study of the Nativis Voyager(TM) System in Patients with Recurrent Glioblastoma Multiforme (GBM)

NCT ID : 02296580
Protocol Number : NAT-101 (20141455)
Phase : Pilot/ Feasibility

Brain Tumors & Neuroscience

Barkhoudarian

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS = 50%) (KEYNOTE-598)

NCT ID : 3302234
Protocol Number : MK 3475-598
Phase : III

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Onugha

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy

NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II

Urology and Urologic Oncology

Wilson

An Open-Label Non-Randomized, Multicenter Phase 2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression

NCT ID : 02858895
Protocol Number : MDNA55-05
Phase : II

Brain Tumors & Neuroscience

Achrol

A Longitudinal Assessment of Tumor Evolution in Patients with Brain Cancer

NCT ID : 3425292
Protocol Number : JWCI-17-0801
Phase : N/A

Brain Tumors & Neuroscience

Kesari

A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer

NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I

Brain Tumors & Neuroscience

Kesari

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

NCT ID : 02646748
Protocol Number : INCB39110-107 (20160236)
Phase : Ib

Gynecologic Oncology

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Urology and Urologic Oncology

O'Day

ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

NCT ID : 3397394
Protocol Number : CO-338-085
Phase : II

Urology and Urologic Oncology

Twardowski

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

NCT ID : NCT03149003
Protocol Number : BBI-DSP7888-201G
Phase : II

Brain Tumors & Neuroscience

Kesari

Recombinant Human Arginase 1 (RhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety And PK/PD

NCT ID : 2285101
Protocol Number : BCT-100-005
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day